193 related articles for article (PubMed ID: 16933153)
1. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
[TBL] [Abstract][Full Text] [Related]
3. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
Goodin S
Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
[TBL] [Abstract][Full Text] [Related]
12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD
Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Villanueva C; Dufresne A; Pivot X; Viel E
Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
Villanueva C; Vuillemin AT; Demarchi M; Bazan F; Chaigneau L; Pivot X
Womens Health (Lond); 2009 Mar; 5(2):115-21. PubMed ID: 19245349
[TBL] [Abstract][Full Text] [Related]
19. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
